본문 바로가기
KERD
논문KCI 등재

허혈뇌졸중에서 비타민 K 비의존경구항응고제의 사용

Use of Non-Vitamin K Dependent Oral Anticoagulant in Ischemic Stroke

유준상|박형종
대한신경과학회 (Korean Neurological Association)|2022.02|대한신경과학회지 (Journal of the Korean Neurological Association)|제40권 제1호|pp. 1-14

1

조회

0

다운로드

1

인용

0

참고문헌

키워드

AnticoagulantsIschemic strokeApixabanRivaroxabanDabigatranEdoxaban
주제분류신경과학

초록

Atrial fibrillation (AF) is associated with an increased incidence of ischemic stroke and transient ischemic attack. A confluence of various factors such as blood stasis, endothelial dysfunction, and prothrombotic state could be contributing to the thrombogenesis in AF. Anticoagulation is the first-line therapy for the prevention of thromboembolism by AF. In current days, non-vitamin K dependent oral anticoagulants (NOAC) are considered as the preferred choice of anticoagulants to prevent ischemic stroke in patients with AF. NOACs have comparable good efficacy and better safety with a predictable anticoagulant effect without the routine coagulation monitoring compared to vitamin K dependent oral anticoagulant. However, the proper use of NOACs needs a careful approach to many practical aspects for balancing the preventing thromboembolic events and bleeding risk. Thus, understanding the drug metabolism and indication of NOAC for a specific situation is essential. In this article, we review major clinical trials, the mechanism, and the use of NOACs in the actual clinical setting of managing ischemic stroke patients.

Abstract

Atrial fibrillation (AF) is associated with an increased incidence of ischemic stroke and transient ischemic attack. A confluence of various factors such as blood stasis, endothelial dysfunction, and prothrombotic state could be contributing to the thrombogenesis in AF. Anticoagulation is the first-line therapy for the prevention of thromboembolism by AF. In current days, non-vitamin K dependent oral anticoagulants (NOAC) are considered as the preferred choice of anticoagulants to prevent ischemic stroke in patients with AF. NOACs have comparable good efficacy and better safety with a predictable anticoagulant effect without the routine coagulation monitoring compared to vitamin K dependent oral anticoagulant. However, the proper use of NOACs needs a careful approach to many practical aspects for balancing the preventing thromboembolic events and bleeding risk. Thus, understanding the drug metabolism and indication of NOAC for a specific situation is essential. In this article, we review major clinical trials, the mechanism, and the use of NOACs in the actual clinical setting of managing ischemic stroke patients

참고문헌 (73)

  1. 정근화, "심방세동과 허혈뇌졸중 또는 일과성허혈발작을 가진환자에서 최신 항혈전치료에 대한 지침", 대한신경과학회지, 34(3), pp.184~192 (2016), 대한신경과학회[DOI]
  2. Kleindorfer DO, "2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack : a guideline from the American Heart Association", American Stroke Association, 2021, pp.52, e364~e467
  3. Connolly SJ, "Dabigatran versus warfarin in patients with atrial fibrillation", N Engl J Med, 361, pp.1139~1151 (2009)
  4. Graham DJ, "Cardiovascular, bleeding, and mortality risks in elderly medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation", Circulation, 131, pp.157~164 (2015)
  5. Granger CB, "Apixaban versus warfarin in patients with atrial fibrillation", N Engl J Med, 365, pp.981~992 (2011)
  6. Connolly SJ, "Apixaban in patients with atrial fibrillation", N Engl J Med, 364, pp.806~817 (2011)
  7. Patel MR, "Rivaroxaban versus warfarin in nonvalvular atrial fibrillation", N Engl J Med, 365, pp.883~891 (2011)
  8. Giugliano RP, "Edoxaban versus warfarin in patients with atrial fibrillation", N Engl J Med, 369, pp.2093~2104 (2013)
  9. 이소령, "Label Adherence for Non-Vitamin K Antagonist Oral Anticoagulants in a Prospective Cohort of Asian Patients with Atrial Fibrillation", Yonsei Medical Journal, 60(3), pp.277~284 (2019), 연세대학교의과대학[DOI]
  10. Blech S, "The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans", Drug Metab Dispos, 36, pp.386~399 (2008)
  11. Steffel J, "2021 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation", Europace, 23, pp.1612~1676 (2021)
  12. Chang SH, "Association between use of non-vitamin K oral anticoagulants with and without concurrent medications and risk of major bleeding in nonvalvular atrial fibrillation", JAMA, 318, pp.1250~1259 (2017)
  13. Stollberger C, "Interactions between non-vitamin k oral anticoagulants and antiepileptic drugs", Epilepsy Res, 126, pp.98~101 (2016)
  14. de Biase S, "Timing use of novel anti-epileptic drugs : Is earlier better?", Expert Rev Neurother, 19, pp.945~954 (2019)
  15. Seiffge DJ, "Timing of anticoagulation after recent ischaemic stroke in patients with atrial fibrillation", Lancet Neurol, 18, pp.117~126 (2019)
  16. Molina CA, "Timing of spontaneous recanalization and risk of hemorrhagic transformation in acute cardioembolic stroke", Stroke, 32, pp.1079~1084 (2001)
  17. Ahmen N, "Recommendation from the ESO-Karolinska stroke update conference, Stockholm 13-15 November 2016", Eur Stroke J, 2, pp.95~102 (2017)
  18. Hindricks G, "2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery(EACTS) : The task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology(ESC)developed with the special contribution of the European Heart Rhythm Association(EHRA)of the esc", Eur Heart J, 42, pp.373~498 (2021)
  19. Mi-Yeon Eun, "Initiation of Guideline-Matched Oral Anticoagulant in Atrial Fibrillation-Related Stroke", 대한뇌졸중영문학회지, 23(1), pp.113~123 (2021), 대한뇌졸중학회[DOI]
  20. Hong KS, "Rivaroxaban vs warfarin sodium in the ultra-early period after atrial fibrillation-related mild ischemic stroke : a randomized clinical trial", JAMA Neurol, 74, pp.1206~1215 (2017)
  21. Pollack CV, Jr., "Idarucizumab for dabigatran reversal - full cohort analysis", N Engl J Med, 377, pp.431~441 (2017)
  22. Connolly SJ, "Full study report of andexanet alfa for bleeding associated with factor xa inhibitors", N Engl J Med, 380, pp.1326~1335 (2019)
  23. Spyropoulos AC, "How i treat anticoagulated patients undergoing an elective procedure or surgery", Blood, 120, pp.2954~2962 (2012)
  24. Douketis JD, "Perioperative management of patients with atrial fibrillation receiving a direct oral anticoagulant", JAMA Intern Med, 179, pp.1469~1478 (2019)
  25. Benesch C, "Perioperative neurological evaluation and management to lower the risk of acute stroke in patients undergoing noncardiac, nonneurological surgery : a scientific statement from the American Heart Association", American Stroke Association, 2021, pp.143, e923~e946
  26. Lip GY, "Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach : the euro heart survey on atrial fibrillation", Chest, 137, pp.263~272 (2010)
  27. Park H, "Impact of the total number of carotid plaques on the outcome of ischemic stroke patients with atrial fibrillation", J Clin Med, 8, pp.1897~ (2019)
  28. Kim JT, "Effectiveness of adding antiplatelets to oral anticoagulants in patients with acute ischemic stroke with atrial fibrillation and concomitant large artery steno-occlusion", Transl Stroke Res, 11, pp.1322~1331 (2020)
  29. Cannon CP, "Dual antithrombotic therapy with dabigatran after pci in atrial fibrillation", N Engl J Med, 377, pp.1513~1524 (2017)
  30. Lopes RD, "Antithrombotic therapy after acute coronary syndrome or pci in atrial fibrillation", N Engl J Med, 380, pp.1509~1524 (2019)
  31. Gibson CM, "Prevention of bleeding in patients with atrial fibrillation undergoing pci", N Engl J Med, 375, pp.2423~2434 (2016)
  32. Dewilde WJ, "Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention : An open-label, randomised, controlled trial", Lancet, 381, pp.1107~1115 (2013)
  33. Lopes RD, "Safety and efficacy of antithrombotic strategies in patients with atrial fibrillation undergoing percutaneous coronary intervention : a network meta-analysis of randomized controlled trials", JAMA Cardiol, 4, pp.747~755 (2019)
  34. Chimowitz MI, "Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis", N Engl J Med, 352, pp.1305~1316 (2005)
  35. Eikelboom JW, "Dabigatran versus warfarin in patients with mechanical heart valves", N Engl J Med, 369, pp.1206~1214 (2013)
  36. Durães AR, "Dabigatran versus warfarin after bioprosthesis valve replacement for the management of atrial fibrillation postoperatively : dawa pilot study", Drugs R D, 16, pp.149~154 (2016)
  37. Guimarães HP, "Rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve", N Engl J Med, 383, pp.2117~2126 (2020)
  38. Shim CY, "Efficacy and safety of edoxaban in patients early after surgical bioprosthetic valve implantation or valve repair : a randomized clinical trial", J Thorac Cardiovasc Surg (2021)
  39. Renda G, "Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and valvular heart disease", J Am Coll Cardiol, 69, pp.1363~1371 (2017)
  40. Kim JY, "Outcomes of direct oral anticoagulants in patients with mitral stenosis", J Am Coll Cardiol, 73, pp.1123~1131 (2019)
  41. Hao L, "Uninterrupted dabigatran versus warfarin in the treatment of intracardiac thrombus in patients with non-valvular atrial fibrillation", Int J Cardiol, 190, pp.63~66 (2015)
  42. Lip GY, "Left atrial thrombus resolution in atrial fibrillation or flutter : Results of a prospective study with rivaroxaban(x-tra)and a retrospective observational registry providing baseline data(clot-af)", Am Heart J, 178, pp.126~134 (2016)
  43. Ezekowitz MD, "Apixaban compared to heparin", vitamin k antagonist in patients with atrial fibrillation scheduled for cardioversion : The emanate trial, 2018, pp.39, 2959~2971
  44. Robinson AA, "Off-label use of direct oral anticoagulants compared with warfarin for left ventricular thrombi", JAMA Cardiol, 5, pp.685~692 (2020)
  45. Caldeira D, "Non-vitamin K antagonist oral anticoagulants in elderly patients with atrial fibrillation : a systematic review with meta-analysis and trial sequential analysis", Arch Gerontol Geriatr, 81, pp.209~214 (2019)
  46. Eikelboom JW, "Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation : An analysis of the randomized evaluation of long-term anticoagulant therapy(re-ly)trial", Circulation, 123, pp.2363~2372 (2011)
  47. Okumura K, "Low-dose edoxaban in very elderly patients with atrial fibrillation", N Engl J Med, 383, pp.1735~1745 (2020)
  48. Park CS, "Increased risk of major bleeding in underweight patients with atrial fibrillation who were prescribed non-vitamin K antagonist oral anticoagulants", Heart Rhythm, 14, pp.501~507 (2017)
  49. Boriani G, "Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the engage af-timi 48 trial", Eur Heart J, 40, pp.1541~1550 (2019)
  50. Hohnloser SH, "Efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation and extremes in body weight", Circulation, 139, pp.2292~2300 (2019)
  51. Lee SR, "Direct oral anticoagulants in patients with nonvalvular atrial fibrillation and low body weight", J Am Coll Cardiol, 73, pp.919~931 (2019)
  52. Steffel J, "2021 European Heart Rhythm Assocaition Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation", Eurospace, 23, pp.1612~1676 (2021)
  53. RuffCT, "Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation : a meta-analysis of randomised trials", Lancet, 383, pp.955~962 (2014)
  54. Burr N, "Risk of gastrointestinal bleeding with direct oral anticoagulants : a systematic review and network meta-analysis", Lancet Gastroenterol Hepatol, 2, pp.85~93 (2017)
  55. Graham DJ, "Stroke, bleeding, and mortality risks in elderly medicare beneficiaries treated with dabigatran or rivaroxaban for nonvalvular atrial fibrillation", JAMA Intern Med, 176, pp.1662~1671 (2016)
  56. Ray WA, "Association of oral anticoagulants and proton pump inhibitor cotherapy with hospitalization for upper gastrointestinal tract bleeding", JAMA, 320, pp.2221~2230 (2018)
  57. Hart RG, "Embolic strokes of undetermined source : The case for a new clinical construct", Lancet Neurol, 13, pp.429~438 (2014)
  58. Hart RG, "Rivaroxaban for stroke prevention after embolic stroke of undetermined source", N Engl J Med, 378, pp.2191~2201 (2018)
  59. Diener HC, "Dabigatran for prevention of stroke after embolic stroke of undetermined source", N Engl J Med, 380, pp.1906~1917 (2019)
  60. Narender Goel, "Anticoagulation in Patients with End-Stage Renal Disease and Atrial Fibrillation: Confusion, Concerns and Consequences", 대한뇌졸중영문학회지, 22(3), pp.306~316 (2020), 대한뇌졸중학회[DOI]
  61. Stanifer JW, "Apixaban versus warfarin in patients with atrial fibrillation and advanced chronic kidney disease", Circulation, 141, pp.1384~1392 (2020)
  62. 정보영, "2018 Korean Guideline of Atrial Fibrillation Management", Korean Circulation Journal, 48(12), pp.1033~1080 (2018), 대한심장학회
  63. Siontis KC, "Outcomes associated with apixaban use in patients with end-stage kidney disease and atrial fibrillation in the united states", Circulation, 138, pp.1519~1529 (2018)
  64. Kuno T, "Oral anticoagulation for patients with atrial fibrillation on long-term hemodialysis", J Am Coll Cardiol, 75, pp.273~285 (2020)
  65. Qamar A, "Oral anticoagulation in patients with liver disease", J Am Coll Cardiol, 71, pp.2162~2175 (2018)
  66. Lee SR, "Direct oral anticoagulants in patients with atrial fibrillation and liver disease", J Am Coll Cardiol, 73, pp.3295~3308 (2019)
  67. Navi BB, "New diagnosis of cancer and the risk of subsequent cerebrovascular events", Neurology, 90, pp.e2025~e2033 (2018)
  68. Oh Young Bang, "Cancer-Related Stroke: An Emerging Subtype of Ischemic Stroke with Unique Pathomechanisms", 대한뇌졸중영문학회지, 22(1), pp.1~10 (2020), 대한뇌졸중학회[DOI]
  69. Powers WJ, "Guidelines for the early management of patients with acute ischemic stroke : 2019 update to the 2018 guidelines for the early management of acute ischemic stroke : a guideline for healthcare professionals from the American Heart Association", American Stroke Association, 2019, pp.50, e344~e418
  70. Raskob GE, "Edoxaban for the treatment of cancer-associated venous thromboembolism", N Engl J Med, 378, pp.615~624 (2018)
  71. Young AM, "Comparison of an oral factor xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism : Results of a randomized trial(select-d)", J Clin Oncol, 36, pp.2017~2023 (2018)
  72. Agnelli G, "Apixaban for the treatment of venous thromboembolism associated with cancer", N Engl J Med, 382, pp.1599~1607 (2020)
  73. Keun-Sik Hong, "Non-Vitamin K Antagonist Oral Anticoagulants in Medical Conditions at High Risk of Thromboembolism beyond Atrial Fibrillation", 대한뇌졸중영문학회지, 21(3), pp.259~275 (2019), 대한뇌졸중학회[DOI]

관련 논문AI추천

Antithrombotic Management of Patients with Nonvalvular Atrial Fibrillation and Ischemic Stroke or Transient Ischemic Attack: Executive Summary of the Korean Clinical Practice Guidelines for Stroke김영대, 나정호, 배희준, 유경호, 윤병우, 이병철, 허지회, Jong-Moo Park, Keun-Hwa Jung, Keun-Sik Hong, Sun U. Kwon대한뇌졸중학회 · 대한뇌졸중영문학회지2015 · 제17권 제2호심방세동과 허혈뇌졸중 또는 일과성허혈발작을 가진환자에서 최신 항혈전치료에 대한 지침권순억, 김영대, 나정호, 박종무, 배희준, 유경호, 윤병우, 이병철, 정근화, 허지회, 홍근식대한신경과학회 · 대한신경과학회지2016 · 제34권 제3호비타민K비의존경구항응고제 사용 후 안정화된 재발뇌경색강진호, 김두응, 김승민, 양영순, 조은경, 하상원, 한상우, 한정호대한신경과학회 · 대한신경과학회지2016 · 제34권 제1호한국 뇌졸중 진료지침에서 심방세동 환자의 뇌졸중 일차예방에 관한 내용의 부분 개정강규식, 구자성, 권순억, 김한영, 나정호, 박종무, 배희준, 오창완, 유경호, 윤병우, 이병철, 조용진, 한상원, 허지회, 홍근식대한뇌졸중학회 · 대한뇌졸중영문학회지2012 · 제14권 제3호Non-Vitamin K Oral Anticoagulants in Stroke Patients: Practical IssuesChristoph Kleinschnitz, Hans-Christoph Diener대한뇌졸중학회 · 대한뇌졸중영문학회지2016 · 제18권 제2호새로운 항응고제의 임상적 적용: 비판막성 심방세동 환자에서 뇌졸중의 예방을 위한 새로운 항응고제의 사용을 중심으로김동민, 이명용대한내과학회 · 대한내과학회지2014 · 제87권 제1호

이 간행물의 다른 논문 (19건)

시신경척수염범위질환 치료의 최신 지견김수현pp. 15-21한국인 환자의 아토르바스타틴에 의한 근육통 발병률에 대한 단일 병원 전향연구: 스타틴근육통 임상지수의 적용김병건, 강규식pp. 22-28기억력 저하를 호소하는 환자에서 음주 여부에 따른 인지기능 차이: 주관적인지 저하, 경도인지장애, 알츠하이머형치매 집단 비교이강수, 임현정, 신정원, 윤정혜, 김미연, 박보미, 이지홍, 김현숙pp. 29-38카다실 환자의 주요혈관인지장애와 경도혈관인지장애에서 뇌 자기공명영상 표지자가 미치는 영향고명주, 이호규, 이정석, 최재철pp. 39-46기계적 혈전제거술 후 지연되어 발생한 증상 중간대뇌동맥협착최재철, 김중구, 고명주, 김민주pp. 47-50
원문 보기